Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 10/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 10/20 | 0.45 |
| ▸ | CACNA1I | Q9P0X4 | 10/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1868065 | 0.76 | S1PR1 (0.37) | CACNA1GCACNA1HCACNA1IS1PR1S1PR3 | |
| SCHEMBL1854014 | 0.76 | S1PR1 (0.37) | CACNA1GCACNA1HCACNA1IS1PR1S1PR3 | |
| SCHEMBL1859548 | 0.76 | CACNA1G (0.52) | CACNA1GCACNA1HCACNA1IS1PR1S1PR3 | |
| SCHEMBL1858733 | 0.75 | S1PR1 (0.42) | CACNA1GCACNA1HCACNA1IS1PR1S1PR3 | |
| SCHEMBL1863267 | 0.74 | S1PR1 (0.35) | CACNA1GCACNA1HCACNA1IS1PR1S1PR3 | |
| SCHEMBL1852730 | 0.73 | CACNA1H (0.49) | CACNA1GCACNA1HCACNA1IS1PR1S1PR3 | |
| SCHEMBL1862056 | 0.66 | S1PR1 (0.69) | S1PR1S1PR3 | |
| SCHEMBL23334742 | 0.64 | CES1 (0.38) | S1PR1KDM4ENPC1LMNAMAPT | |
| SCHEMBL26037624 | 0.64 | CES1 (0.40) | S1PR1S1PR3 | |
| SCHEMBL23334740 | 0.64 | L3MBTL1 (0.34) | KDM4ENPC1LMNAMAPTNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039644-B2 | Hydrogenated benzo (C) thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| US-7981924-B2 | Thiophene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-07-19 | — | — | US | disclosed |
| EP-1863787-B1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-20100204198-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-08-12 | — | — | US | disclosed |
| US-7723378-B2 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-05-25 | — | — | US | disclosed |
| US-20080300294-A1 | Novel Thiophene Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-12-04 | — | — | US | disclosed |
| EP-1954688-A1 | NOVEL THIOPHENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-08-13 | — | — | EP | disclosed |
| US-20080176926-A1 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-07-24 | — | — | US | disclosed |
| EP-1863787-A1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007060626-A1 | NOVEL THIOPHENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006100631-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204198-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | NFATC1, ICOS, TPMT | CACNA1G 3287/4885CACNA1H 3746/4885CACNA1I 3339/4885 |
| US-20080300294-A1 | Novel Thiophene Derivatives | TPMT, TSLP, NFATC1 | CACNA1G 3634/4885CACNA1H 3662/4885CACNA1I 3613/4885 |
| US-20080176926-A1 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | S1PR1, S1PR3, S1PR5 | CACNA1G 483/4885CACNA1H 1305/4885CACNA1I 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.